WO2001078649A2 - Composition medicale pharmaceutique - Google Patents

Composition medicale pharmaceutique Download PDF

Info

Publication number
WO2001078649A2
WO2001078649A2 PCT/RU2001/000154 RU0100154W WO0178649A2 WO 2001078649 A2 WO2001078649 A2 WO 2001078649A2 RU 0100154 W RU0100154 W RU 0100154W WO 0178649 A2 WO0178649 A2 WO 0178649A2
Authority
WO
WIPO (PCT)
Prior art keywords
substances
effective
pollen
efficient
effective substances
Prior art date
Application number
PCT/RU2001/000154
Other languages
English (en)
Russian (ru)
Other versions
WO2001078649A3 (fr
Inventor
Alexandr Andreevich Zarubin
Original Assignee
Alexandr Andreevich Zarubin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexandr Andreevich Zarubin filed Critical Alexandr Andreevich Zarubin
Priority to AU2001248943A priority Critical patent/AU2001248943A1/en
Publication of WO2001078649A2 publication Critical patent/WO2001078649A2/fr
Publication of WO2001078649A3 publication Critical patent/WO2001078649A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • P ⁇ edlagae maya medical ⁇ m ⁇ zitsiya m ⁇ zhe ⁇ by ⁇ ⁇ imenen ⁇ ⁇ i nev ⁇ za ⁇ , vege ⁇ -s ⁇ sudis ⁇ y dis ⁇ nii for ⁇ edu ⁇ ezhdeniya ⁇ azvi ⁇ iya ⁇ u ⁇ ley in ⁇ m ⁇ le ⁇ sn ⁇ m treatment ⁇ niches ⁇ i ⁇ zab ⁇ levany, ⁇ sle ⁇ e ⁇ eneseniya ⁇ yazhely ⁇ ⁇ e ⁇ a ⁇ ev ⁇ iches ⁇ i ⁇ and ⁇ i ⁇ u ⁇ giches ⁇ yu zab ⁇ levany, ⁇ i as ⁇ eniches ⁇ i ⁇ , s ⁇ ess ⁇ vy ⁇ s ⁇ s ⁇ yaniya ⁇ , ⁇ vyshen- n ⁇ y u ⁇ mlyaem ⁇ s ⁇ i, ⁇ i alle ⁇ giches ⁇ i ⁇ ⁇ ea ⁇ tsiya ⁇ , cholesterol> athe
  • Another disadvantage is that its components do not contain biologically active substances that may be hazardous.
  • the well-known vitamin-rich complex contains the extracts of flower pollen, the extract of the product of the product, the extract of the product. Vitamin C, Vitamin ⁇ , Calcium, Talc and Lactose.
  • the known foods of the vitamin complex are the limited range of applications. Another disadvantage is the possible manifestations of allergic reactions to vitamins C and ⁇ , as a result, for people suffering from virulent diabetes.
  • ⁇ ⁇ edlagaem ⁇ m ⁇ e ⁇ niches ⁇ m ⁇ eshenii was ⁇ s ⁇ avlena za- cottage s ⁇ zdaniya ⁇ a ⁇ matsev ⁇ iches ⁇ y lechebn ⁇ y ⁇ m ⁇ zitsii shi ⁇ gs dia ⁇ az ⁇ na izlechivaemy ⁇ za ⁇ levany tsen ⁇ aln ⁇ y ne ⁇ vn ⁇ y sis ⁇ e- we ⁇ a ⁇ i ⁇ ⁇ a ⁇ nev ⁇ zy, vege ⁇ a ⁇ ivn ⁇ -s ⁇ sudis ⁇ aya dis ⁇ niya, gi ⁇ e ⁇ - Niya, shiz ⁇ eniya in s ⁇ adii ⁇ emissii ⁇ as ⁇ eniches ⁇ mu ⁇ i ⁇ u, as ⁇ e- niches ⁇ y Sind ⁇ m, ⁇ yavlyaemy in general weakness, decrease in distress, memory, increased discomfort, dyspe
  • Efficient substances of the business environment 0.200 - 0.230 Efficient substances of the left-hand side 0, 100 - 0, 150 Efficient substances of the elemental 0, 100 - 0, 150
  • the effective substances of the left-hand side are complex 0,100 - 0,150
  • the effective substances of the white lily 0.010 - 0.015 The effective substances of the white lily 0.130 - 0.140 Family milk 0.616 - 0.012
  • Efficient substances of the business environment 0.200 - 0.230 Efficient substances of the left-hand side with a specific 0, 100 - 0, 150 Efficient substances of the eleuthera 0, 100 - 0, 150
  • the effective substances of the left-hand side are complex 0.100 - 0.150
  • the effective substances the mummy are the cleaned materials 0, 100 - 0, 0, 00 living substances 0, 100 - 0, 006
  • the effective substances of the environment 0.015 - 0.017 The effective substances of the white lily 0.010 - 0.015
  • the effective substances of the barvinque product are 0.002 - 0.010; the default is 0.010 - 0.015
  • Fresh oil 0.564 - 0.600 A solution to the fixed problem is also achieved, including i ⁇ edlagaomaya ⁇ a ⁇ matsev ⁇ iches ⁇ aya therapeutic ⁇ m ⁇ zitsiya d ⁇ lni- ⁇ eln ⁇ s ⁇ de ⁇ zhi ⁇ e ⁇ s ⁇ a ⁇ ivnye vesches ⁇ va bezv ⁇ emenni ⁇ a veli ⁇ - le ⁇ n ⁇ g ⁇ ⁇ i following mass ⁇ v ⁇ y ⁇ ntsen ⁇ atsii in g: E ⁇ s ⁇ a ⁇ ivnye vesches ⁇ va ⁇ lisa 0.003 - 0.010 Es ⁇ a ⁇ ivnye vesches ⁇ va ⁇ di ⁇ ly ⁇ z ⁇ v ⁇ y 0.200 - 0.230
  • the effective substances of the left-hand side are complex 0,100 - 0,150
  • the proposed pharmaceutical treatment for young people was also carried out in a different medicinal form, for example. in ⁇ even.
  • the proposed pharmaceutical treatment for young people was performed in the form of capsules, a large amount of gelatin.
  • the proposed pharmaceutical equipment may optionally contain a chewable component.
  • the proposed therapeutic benefit may be implemented in the form of a concentrated process of dealing with active substances.
  • the proposed pharmaceutical treatment for the patients may be performed in the form of candles.
  • the proposed basic pharmaceutical treatment includes the addition of one of the most productive: neglected or non-beneficial
  • the yuuuuuuuuuuuuuuuuuuuuuuuuyu tsvetstvennymi material levzei somploobraznym in the composition of the composition is 0.120 g.
  • the 2 nd general balance of the organism including the one stimulating the mental and physical workability of a person.
  • the optimal content of efficient substances in the elec- tron is $ 0.120 in commerce; however, this consumes the cost of the business.
  • the best performance ratio of the components in the offered components is obtained by keeping * the material is clean; the product has been cleaned for about 0.100
  • Exclusion in the composition of the com- pact of efficient substances of flower pollen containing vitamins, pomegranates, foodstuffs, fats. water and urban substances, ensures the therapeutic impact of the claimed interest on civilization. ⁇ a ⁇ imer ⁇ .
  • the optimal content of productive elecampane is at least 0.010 to 0.050 g. With this content, the most effective impact on the human body is observed, including tuberculosis, jaundice, and diabetes.
  • the optimal ratio of components in the proposed distribution is achieved by the use of components of efficient products from 0.015 to 0.017g.
  • the optimal content of efficient substances is more profitable in commerce, which is 0.011.
  • the optimal content of productive substances in the bulk of the commercially available is 0.005 g. In this case, there is a greater share of the share of the property.
  • this pharmaceutical treatment component ensures complete absorption of substances in a biologically active way up to 8 hours.
  • a pharmaceutical therapeutic combination may be used. for the manufacture of concentrate and syrup.
  • Concentrated system on the basis of the proposed com- pensation additionally contains carbohydrates, organic acid.
  • the carbohydrate content is g / 100 cm 3 : 34,000 - 46,000. This content of carbohydrates is optimal and ensures the necessary organic products of ready-made food products.
  • the optimal carbohydrate content is 40,000 g / 100 cm 3 . With this content, the concentrated syrup is the best tasting flavor.
  • the content of organic acids is, as a rule, a short-lived essence is offered, which is, g / 100 cm 3 : 0 0.00000015 ds 0.00000025. This acid content is optimal. With this content, you will be able to ensure that the system is priced on the basis of the best available, umpteenth, tamper-prone incidents.
  • the claimed pharmaceutical medical treatment has been purchased for seven years. Research was done by the beneficiaries. The results of the studies were compared with the results obtained by testing the composition and the method of its application to health people.
  • liver, liver, gastric intestinal tract normalization of the condition of patients with diseases of the endocrine glands, including pancreas, are noted.
  • ⁇ -shaped glands are noted.
  • the care provider may be subject to the condition and well-being of the patient and to the analysis.
  • the claimed invention may be successfully applied to medicine, food and food industry. This arrangement may have been produced many times.
  • the type of syndrome is an acute syndrome, manifested in general weakness, a decrease in working capacity, memory, and discomfort. headaches, sleeplessness, and also vegetative diseases. sympathetic, parasympathetic, endocrine system, urology - 5 garlic and gynecological diseases.
  • the pharmaceutical medical treatment is prepared in the following way.
  • the added oil is added to +50 ° C for some oil. 15 All components interfere with the receipt of a single input.
  • the resulting material is poured into the form and cooled to a temperature of +20 - 25 ⁇ C for a short time.
  • the effective substances of resin are 0.003
  • the weight of the candle made from this combination, complies with U and is equal to 1.55 g.
  • EXAMPLE. 2 A pharmaceutical treatment was prepared in the form of a candle in accordance with ⁇ U, containing the following substances in mass concentration in g:
  • the effective substances of the left-hand side are complex 0.100
  • EXAMPLE 4 A pharmaceutical treatment was prepared in the form of a candle according to the law, containing the following substances and mass concentration in g:
  • EXAMPLE ⁇ 6 A pharmaceutical treatment was prepared in the form of a candle according to the agreement containing substances of the following mass concentration in the city: Active substances of 0,060
  • Example 7 A pharmaceutical treatment was prepared in the form of a candle according to the following mass concentration in g:
  • the productive substances of the business area are 0.200
  • the productive materials of the left-handed group is 0.100
  • the effective substances of resin are 0.004
  • EXAMPLE ⁇ 10 Shalva S., 75 years old, diagnoses: adenoma, diabetes mellitus, blood pressure 200/100 mm. ⁇ . ct. In the past, there was a stroke and an infarction, one stroke, could not lie down and fall on the left big blue. I experienced a small amount of pain in my stomach. "P ⁇ sle ⁇ iem ⁇ ” ⁇ itoge ⁇ na "in the form of suppositories for 25 days ⁇ 2 candles in dash nas ⁇ u ⁇ il ⁇ ⁇ bezb ⁇ livanie.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Vascular Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention relève de la médecine, de la fabrication de compositions médicinales à base de produits naturels ainsi que des industries alimentaire et des concentrés d'aliments. Elle concerne la fabrication de produits médicaux à partir de matières premières naturelles, d'un minéral liquide à poids moléculaire élevé, de résines d'origine végétale, de lipides végétaux et de produits d'apiculture. La composition médicinale peut s'utiliser pour traiter les névroses et l'angioneurose, dans la prévention de la croissance tumorale, dans le traitement intégré de maladies chroniques, après des maladies aiguës thérapeutiques et chirurgicales, lors des états de stress et d'asthénie, en cas de fatigabilité élevée, lors des réactions allergiques et d'athéroscléroses liées au cholestérol. L'invention permet de créer une composition médicinale qui peut s'utiliser en proctologie, urologie, gynécologie, gastro-entérologie, pour la normalisation du fonctionnement des systèmes végétatif, sympathique, parasympathique, endocrinien, pour diminuer les réactions allergiques, augmenter l'activité antitumorale et antimétastasique ainsi que la résistance de l'organisme aux conditions environnementales défavorables et améliorer l'endurance mentale et physique. La composition pharmaceutique comprend des substances médicinales sous forme d'essences de propolis, de Rhodiola rosea et de pollen de fleurs ainsi que des essences dialcoolisées, y compris celles de Leuzea carthamoides, d'Eleutherococcus, de 'mumio', de sève de pins, d'Inula helenium, d'Amaryllis belladonna, de lys blanche ainsi que de la gelée royale, de la poudre de pollen de fleurs et de l'huile de cacao, avec une proportion appropriée des composants. L'invention comprend des exemples avec des ingrédients supplémentaires.
PCT/RU2001/000154 2000-04-17 2001-04-17 Composition medicale pharmaceutique WO2001078649A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001248943A AU2001248943A1 (en) 2000-04-17 2001-04-17 Pharmaceutical curative compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2000109750/14A RU2174003C1 (ru) 2000-04-17 2000-04-17 Фармацевтическая лечебная композиция, способ лечебного и лечебно-профилактического ее применения
RU2000109750 2000-04-17

Publications (2)

Publication Number Publication Date
WO2001078649A2 true WO2001078649A2 (fr) 2001-10-25
WO2001078649A3 WO2001078649A3 (fr) 2002-03-07

Family

ID=20233529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2001/000154 WO2001078649A2 (fr) 2000-04-17 2001-04-17 Composition medicale pharmaceutique

Country Status (3)

Country Link
AU (1) AU2001248943A1 (fr)
RU (1) RU2174003C1 (fr)
WO (1) WO2001078649A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2487717C1 (ru) * 2011-12-05 2013-07-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Саратовский государственный технический университет имени Гагарина Ю.А." (СГТУ имени Гагарина Ю.А.) Способ повышения физической работоспособности
CN103535730A (zh) * 2013-11-01 2014-01-29 王颖 一种红景天精华物质的提取方法
CN107613994A (zh) * 2015-05-20 2018-01-19 株式会社山田养蜂场本社 泌尿器官症状改善剂

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202006004962U1 (de) 2006-03-28 2007-08-02 Huber, Klaus, Dr.med. Verwendung von Nisylen, Cepa, Euphrasia, Belladonna und/oder Mercurius solubilis für ein Arzneimittel
RU2324492C1 (ru) * 2006-12-04 2008-05-20 Общество с ограниченной ответственностью "Березовый мир" Средство для профилактики и лечения болезни паркинсона
MD20070085A (ro) * 2007-03-26 2009-02-28 Национальный Фармацевтический Университет Compoziţie farmaceutică pentru tratamentul prostatitei
RU2456012C1 (ru) * 2010-11-08 2012-07-20 Учреждение Российской академии наук Институт мозга человека им. Н.П. Бехтеревой Средство для лечения астенического синдрома у больных рассеянным склерозом
RU2521324C1 (ru) * 2013-03-14 2014-06-27 Федеральное Бюджетное Учреждение Науки "Нижегородский Научно-Исследовательский Институт Гигиены И Профпатологии" Федеральной Службы По Надзору В Сфере Защиты Прав Потребителей И Благополучия Человека (Фбун "Нниигп" Роспотребнадзора) Способ коррекции морфофункционального состояния спортсменов

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2033798C1 (ru) * 1993-12-20 1995-04-30 Евгений Иванович Трифонов Средство для апитерапии и апипрофилактики
US5665393A (en) * 1996-09-03 1997-09-09 International Medical Research, Inc. Herbal composition for treating prostate carcinoma
RU2100026C1 (ru) * 1997-02-27 1997-12-27 Чумаян Саида Пайлаковна Средство для местного применения "астхик", обладающее антиинфекционным, антиаллергическим, обезболивающим, рассасывающим, регенерирующим, восстанавливающим и повышающим сопротивляемость организма свойствами
RU2125815C1 (ru) * 1997-07-08 1999-02-10 Удинцев Сергей Николаевич Биологически-активная пищевая добавка "адаптовит"
WO1999052538A1 (fr) * 1998-04-09 1999-10-21 Santillo Humbart D Jr Composition contenant une substance medicinale phytotherapique et un medicament pharmaceutique
RU2142789C1 (ru) * 1997-09-03 1999-12-20 Щербак Игорь Федорович Лекарственное вещество суппозитория с природными продуцентами
RU2146920C1 (ru) * 1998-10-30 2000-03-27 Сараф Александр Сергеевич Комплексный природный препарат в виде суппозиториев для лечения урологических, проктологических и гинекологических заболеваний и способ его получения

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2033798C1 (ru) * 1993-12-20 1995-04-30 Евгений Иванович Трифонов Средство для апитерапии и апипрофилактики
US5665393A (en) * 1996-09-03 1997-09-09 International Medical Research, Inc. Herbal composition for treating prostate carcinoma
RU2100026C1 (ru) * 1997-02-27 1997-12-27 Чумаян Саида Пайлаковна Средство для местного применения "астхик", обладающее антиинфекционным, антиаллергическим, обезболивающим, рассасывающим, регенерирующим, восстанавливающим и повышающим сопротивляемость организма свойствами
RU2125815C1 (ru) * 1997-07-08 1999-02-10 Удинцев Сергей Николаевич Биологически-активная пищевая добавка "адаптовит"
RU2142789C1 (ru) * 1997-09-03 1999-12-20 Щербак Игорь Федорович Лекарственное вещество суппозитория с природными продуцентами
WO1999052538A1 (fr) * 1998-04-09 1999-10-21 Santillo Humbart D Jr Composition contenant une substance medicinale phytotherapique et un medicament pharmaceutique
RU2146920C1 (ru) * 1998-10-30 2000-03-27 Сараф Александр Сергеевич Комплексный природный препарат в виде суппозиториев для лечения урологических, проктологических и гинекологических заболеваний и способ его получения

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2487717C1 (ru) * 2011-12-05 2013-07-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Саратовский государственный технический университет имени Гагарина Ю.А." (СГТУ имени Гагарина Ю.А.) Способ повышения физической работоспособности
CN103535730A (zh) * 2013-11-01 2014-01-29 王颖 一种红景天精华物质的提取方法
CN107613994A (zh) * 2015-05-20 2018-01-19 株式会社山田养蜂场本社 泌尿器官症状改善剂
US20180140643A1 (en) * 2015-05-20 2018-05-24 Yamada Bee Company, Inc. Urinary system symptom amelioration agent

Also Published As

Publication number Publication date
RU2174003C1 (ru) 2001-09-27
AU2001248943A1 (en) 2001-10-30
WO2001078649A3 (fr) 2002-03-07

Similar Documents

Publication Publication Date Title
Bartram Bartram's encyclopedia of herbal medicine
JP5667358B2 (ja) 柑橘類果皮の麹菌発酵組成物
WO2008077614A2 (fr) Utilisation d'une composition de substances minérales et éventuellement de bactéries acétogènes et/ou butyrogènes pour empêcher ou diminuer la formation de gaz dans le gros intestin d'un mammifère et les douleurs abdominales qui en résultent
WO2005102372A1 (fr) Compositions de correction de changements du systeme endocrinien humain dus a l'age et procede de fabrication d'une forme pharmaceutique sur la base de ces compositions
CN102160664A (zh) 儿童营养饮料
CN102014893A (zh) 用于治疗软骨障碍的多酚类
WO2001078649A2 (fr) Composition medicale pharmaceutique
WO1995022336A1 (fr) Agent immunomodulateur et reducteur du dysfonctionnement du systeme de regulation de la propagation de cellules tissulaires
Walls Herbs and natural therapies for pregnancy, birth and breastfeeding
CN101716187A (zh) 一种用于促进排铅、增强免疫力的口服液及其制备方法
CN102362936A (zh) 鸡爪芋提取物的用途及其药品和保健品固体制剂、饮料制剂
RU2381806C1 (ru) Способ лечения желудочно-кишечных болезней телят
JPS6163618A (ja) 下剤
AU2021100330A4 (en) A Kind Of Gamma-Aminobutyric Acid Composition Rich In Botanical Herbs And Its Preparation Method
WO1995008318A2 (fr) Substance medicinale a proprietes anti-infecteuses destinee a etre utilisee dans le traitement de la sterilite et dans la protection de la grossesse
RU2341276C1 (ru) Способ профилактики желудочно-кишечных заболеваний новорожденных телят
CN110720527A (zh) 一种中药减肥茶
PL208040B1 (pl) Zastosowanie preparatu z przecieru z owoców papai Carica papaya do produkcji środka do leczenia zaburzeń trawiennych
Dye Aromatherapy for Women & Children: Pregnancy and Childbirth
WO2024087865A1 (fr) Boisson de fermentation de pitaya d'aide à l'endormissement et son procédé de préparation
RU2216204C2 (ru) Способ подготовки семян для приготовления пищевых проростков
RU2070050C1 (ru) Средство для стимуляции моторно-эвакуаторной функции кишечника у детей
Mironenko et al. Vitamin D–description, benefits and where it is contained
CN118267423A (zh) 一种缓解痛经的组合物及其制备方法和应用
WO2004073724A1 (fr) Composition pharmaceutique endogene, obtenue par une activation dirigee des mediateurs humoraux de terminaisons nerveuses du cortex

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP